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ABSTRACT: Background: Although levodopa is
the most effective oral PD therapy, many patients
experience motor fluctuations, including sudden loss of
dose effect and delayed benefit. CVT-301 is a levodopa
inhalation powder with the potential for rapid onset of
action. The objective of this study was to evaluate
CVT-301 self-administered by PD patients to relieve
OFF episodes.
Methods: PD patients with 2 hours per day of OFF
time despite oral levodopa 4 times per day were
randomized to CVT-301 or placebo for 4 weeks, to be
used up to 3 times per day for OFF episodes. After 2
weeks, the study-drug dose was escalated from 35 to
50 mg. The primary end point was mean change in
UPDRS Part III score from a predose OFF state to the
average of postdose scores obtained at 10, 20, 30, and
60 minutes, as assessed in-clinic at the end of week 4.
Home diaries were recorded.
Results : Eighty-six patients used the study drug at an
average frequency of 2.1 times per day for CVT-301
and for placebo. At 4 weeks, least-squares mean
change in UPDRS Part III score favored CVT-301 by 7.0
points (P < 0.001). A treatment effect was evident at 10
minutes. At 4 weeks, least-squares mean OFF-time
change from baseline favored CVT-301 by 0.9 hours per
day (P 5 0.045). The most frequently reported adverse
events in the CVT-301 group were dizziness, cough,
and nausea, each in 7% (3 of 43 patients).
Conclusions: CVT-301 self-administered during OFF
episodes provided rapid improvement of motor function,
and daily OFF time was significantly reduced at the higher
dose. CVT-301 was generally safe and well-tolerated.
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Levodopa (LD) administered in combination with a
dopa-decarboxylase inhibitor (DDI; carbidopa or ben-
serazide) is the most effective oral treatment for the
motor features of Parkinson’s disease (PD).1 As PD
progresses, however, many patients gradually lose a
predictable and sustained response to each LD dose.2-8
Motor fluctuations manifested as OFF time affect an
estimated 40% of LD-treated PD patients after 4 to 6
years of LD use, increasing to an estimated 70% after
9 years,3 and can have a major impact on a patient’s
function, safety, and quality of life.9 Irregular intesti-
nal absorption of oral LD contributes to delayed or
unpredictable LD benefit.10,11 Strategies including
shorter LD dosing interval, adjunctive drugs, and
sustained-release formulations of oral LD have not
resolved these problems.12
CVT-30113,14 is a novel LD inhalation powder for-
mulated for pulmonary absorption and administered
using a passive, breath-actuated delivery system15 that
has undergone extensive clinical testing for the delivery
of inhaled agents ranging from small molecules16 to
proteins.17,18 In a phase 2a dose-finding, CVT-301
study with a crossover design, 24 PD patients received
single in-clinic doses of standard oral LD and each of 3
inhaled double-blind treatments: placebo, CVT-301 as
a 25-mg fine-particle dose (FPD), and CVT-301 as a
50-mg FPD.19 In each instance, the FPD is the quantity
of LD estimated to reach the lungs. Each treatment was
administered during an OFF episode occurring 4 to 5
hours after the patient’s first daily oral levodopa dose
(plus a DDI) with or without other PD medications.
After the CVT-301 inhalations, plasma LD concentra-
tions were found to increase more rapidly and with less
variability than was observed in the same patients after
oral LD dosing. Improved motor function, as assessed
by timed finger-tapping20 and by Part III motor-
examination scores on the Unified Parkinson’s Disease
Rating Scale (UPDRS),21 was recognized at the first
assessment point, 5 minutes and 15 minutes, respec-
tively. The improvements persisted through assessments
at 90 minutes. After CVT-301 inhalations, the only
adverse event reported by more than 1 patient was
cough, in 6 patients (25%). No serious or severe
adverse events were reported, and patients exhibited no
decline in pulmonary function test results. The objective
of the current phase 2b study was to evaluate the effi-
cacy and safety of CVT-301 self-administered by PD
patients in a clinical setting and at home during OFF
episodes.
Methods
This was a 4-week, randomized, double-blind,
placebo-controlled, multicenter, parallel-group dose-
escalation trial. The trial included a screening period
lasting 2 to 4 weeks, a treatment period lasting 4
weeks, and a follow-up safety visit 1 week after the
end of treatment. The trial was conducted at 13 sites
in the United States, 3 in Italy, 2 in Serbia, and 2 in
the United Kingdom and was registered with
ClinicalTrials.gov (identifier: NCT01777555).
Study Participants
All patients were required to be 30 to 80 years of
age and have typical clinical features of PD. Each
patient also had a modified Hoehn and Yahr (H&Y)
rating22 of stages 1-3 in the ON state and recogniz-
able, predictable OFF episodes totaling  2 hours per
day (excluding early-morning OFF time). Each
patient’s UPDRS Part III scores were required to show
a 25% decrease (improvement) from OFF to ON in
response to the patient’s usual morning dose of LD. In
the ON state, the patient’s forced expiratory volume
during the first second of expiration (FEV1) was
required to be >60% of the value predicted by the
patient’s age, sex, height, and race,23 and the ratio of
FEV1 to forced vital capacity was required to be
75%. The patient’s PD medications were required to
include oral LD taken at least 4 times daily in a regi-
men stable for at least 2 weeks prior to screening. PD
treatment could also include stable dosages of other
marketed oral PD medications (dopaminergic agonists,
monoamine oxidase B inhibitors, catechol-O-methyl-
transferase inhibitors, amantadine, and anticholiner-
gics). Exclusion criteria included a history of chronic
respiratory disease within the preceding 5 years and a
Mini-Mental State Examination24 score < 25.
Study Design
As part of their screening, all patients were taught
how to prepare and use the inhaler system, using
sham drug capsules. The training took place during an
ON state and was repeated during the subsequent
OFF state and also at a second screening visit. By an
interactive web response system, enrolled patients
were randomized in a 1:1 ratio to self-administer
inhaled CVT-301 or placebo for 4 weeks to treat OFF
episodes on an as-needed basis up to 3 times/day. The
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randomization was stratified by baseline PD severity,
as measured by H&Y stage at screening (<2.5 vs
2.5). During weeks 1 and 2, patients used a 35-mg
LD FPD or indistinguishable placebo (the content of
2 capsules). During weeks 3 and 4, patients used a
50-mg LD FPD or placebo (the content of 3 capsules).
Placebo was supplied as an inhalation-grade lactose
monohydrate designed to produce a sensation of dose
administration and approximate the upper respiratory
powder-load deposition of the active drug but not
enter the lungs. Throughout the study, each patient’s
usual regimen of PD medications was held constant,
and apomorphine was not permitted.
Efficacy Assessments
At the beginning of treatment and at the end of
weeks 1, 2, and 4, each patient prepared and self-
administered an in-clinic study-drug dose. At the end of
weeks 2 and 4, the dose was 3 capsules (beginning and
ending the patient’s use of this dose level). At the end
of weeks 1, 2, and 4, the preparation and self-dosing
occurred in an investigator-confirmed OFF state.
UPDRS Part III scores were obtained at screening
and at the end of weeks 1, 2, and 4. During each of
the latter 3 visits, scores were obtained for the predose
OFF state and the 10-, 20-, 30-, and 60-minute post-
dose by an investigator blinded to treatment group. In
addition, each patient was rated subjectively as achiev-
ing or not achieving an ON state during the 60-
minute observation period. At the end of weeks 2 and
4, patients used the Patient Global Impression of
Change (PGI-C) Scale25 to respond to the question
“How has the addition of study drug changed your
Parkinson’s disease?” The scale offers 7 ratings, from
“much improved” to “much worse.” For the 3 days
preceding every visit, patients maintained a home PD
diary26 in which they recorded their predominant clin-
ical state during each half-hour of the waking day as
OFF, ON with no dyskinesia, ON with nontrouble-
some dyskinesia, or ON with troublesome dyskinesia.
Ease of inhaler-system use was not formally assessed.
However, study sites recorded the amount of time a
patient needed for each in-clinic use, and during week
2, a protocol-specified telephone contact elicited
patients’ concerns.
Statistical Methods
The study’s predefined primary efficacy end point
was each treatment group’s least-squares (LS) mean
change from predose UPDRS Part III score to the aver-
age postdose score (across the 10- to 60-minute assess-
ment times) at the end of week 4. The end point was
tested for a significant difference between CVT-301
50 mg and placebo (defined as P < 0.05), using a
mixed model for repeated measurements (MMRM)
with baseline H&Y stage (<2.5 vs 2.5), country,
treatment group, visit, and treatment-by-visit interac-
tion as fixed factors and baseline UPDRS Part III
OFF-state score as a covariate. UPDRS Part III find-
ings at other visits were tested in the same way, as
predefined secondary end points. The proportions of
patients achieving predefined UPDRS Part III score
reductions of at least 3, 6, and 11 points at each post-
dose assessment point were evaluated descriptively.
The proportion of patients rated as achieving an ON
state at a given visit was also assessed descriptively.
PGI-C responses were collapsed into 3 categories:
“improved,” “no change,” and “worse.” The resulting
response distributions were assessed descriptively as a
predefined exploratory efficacy outcome. All diary
data were normalized to a 16-hour waking day by
extrapolation of valid entries after exclusion of time
asleep. For each clinical-state category, LS mean
changes from baseline values (obtained during screen-
ing) were analyzed by an MMRM as predefined sec-
ondary end points.
Sample-Size Calculation
Twenty-nine patients per treatment group was esti-
mated to provide a power of 90% to detect a group
difference of 5.3 points in the primary end point
(within the range considered a moderate clinically
important difference [CID]27), assuming a standard
deviation (SD) of 6.1 points (based on previous studies
and historical data). To overcome a predicted dropout
rate of 30%, the total planned enrollment was
40 patients per group.
Safety Assessments
Safety was assessed descriptively by measures includ-
ing treatment-emergent adverse events (TEAEs), physi-
cal examination findings, clinical laboratory values,
electrocardiography, and spirometry. All spirometry
was performed by qualified, trained personnel using
standardized equipment under guidelines specified by
the Third National Health and Nutrition Examination
Survey, the American Thoracic Society, and the Euro-
pean Respiratory Society.23,28 At screening, spirometry
included examinations in each patient’s ON and OFF
states during a single visit. At each visit during the
treatment period, spirometry was performed on
patient arrival. At the visits initiating the use of each
study-drug dose level (ie, the beginning of week 1 and
the end of week 2), spirometry was also performed
immediately predose and 15, 30, and 60 minutes
postdose.
Ethical Conduct
The study was conducted in accordance with ethical
principles originating in the Declaration of Helsinki,
Good Clinical Practices, and local regulatory
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requirements. Before any study procedures, the study
protocol, investigational drug brochure, and informed
consent forms were approved by appropriately consti-
tuted independent ethics committees and institutional
review boards, and patients provided written informed
consent.
Results
Study Participants
Patient disposition is summarized in Figure 1. Of
134 patients screened at 20 sites, beginning in April
2013, 89 were enrolled and randomized. Among
them, 86 patients (97%) used at least 1 dose of study
drug (thereby comprising the study’s modified intent-
to-treat population), and 75 (87%) completed the
study, the last in January 2014.
Average age 6 SD of study participants was 62.4 6
8.7 years, with PD diagnosed an average of 9.4 6 3.9
years previously. Their mean OFF time, as recorded in
their PD diaries, was 5.8 6 2.0 hours per day, includ-
ing early-morning OFF time. Their mean LD intake
was 770 6 306 mg/day, divided into 5.9 6 1.9 daily
doses. However, the mean LD intake was lower and
MAO-B inhibitor use more common in the CVT-301
group than in the placebo group (Table 1).
Study-Drug Exposure
Patients used the study drug on an average of 24.3
6 6.7 days in the CVT-301 group and 24.4 6 7.7
days in the placebo group over a total period averag-
ing 28.4 6 5.4 days in the CVT-301 group and 26.7
6 7.6 days in the placebo group. The average dosing
frequency over the total period was 2.1 6 0.6 doses/
day in the CVT-301 group and 2.1 6 0.7 doses/day in
the placebo group.
Ease of Inhaler Use
During in-clinic OFF episodes, patients completed 2-
capsule self-dosing in a mean 1.5 6 1.0 minutes and
3-capsule self-dosing in a mean 1.9 6 0.9 minutes.
Across all telephone contacts, 14% of the CVT-301
group (6 of 42 contacted patients) and 7% of the pla-
cebo group (3 of 41 contacted patients) had concerns
about inhaler system use. The only complaint by more
than 1 patient was difficulty puncturing capsules (by 2
CVT-301 users and 1 placebo user).
Efficacy by UPDRS Part III Score
By in-clinic assessment, mean change from predose to
average postdose UPDRS Part III score showed statisti-
cally significant dose-ordered improvement in motor
function after CVT-301 inhalation during an OFF epi-
sode (Supplemental Figure A). For 35 mg, the LS mean
change in UPDRS Part III score was -9.9 points at the
end of week 1 compared with -5.3 points in patients
taking placebo, a treatment effect of -4.6 points (95%
confidence interval [CI], -7.9 to -1.3 points; P 5 0.007).
One week later, the first dosing of 50 mg yielded an LS
mean change of -10.2 points compared with -3.5 points
for the placebo, a treatment effect of -6.6 points (95%
CI, -9.8 to -3.4 points; P < 0.001). At the end of week
4, the LS mean change was –10.0 points for 50 mg ver-
sus -3.1 points for the placebo, a treatment effect of -
7.0 points (primary efficacy analysis; 95% CI, -10.3 to
-3.6; P < 0.001). In the 27 CVT-301-group and
FIG. 1. Patient disposition. AE, adverse event.
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26 placebo-group patients with a baseline H&Y rating
< 2.5, the treatment effect at the end of week 4 was
-4.7 points (95% CI, -9.2 to -0.1 points; P 5 0.044). In
the 16 and 17 patients with a baseline H&Y rating
 2.5, it was -10.2 points (95% CI, -15.7 to -4.6 points;
P < 0.001).
Figure 2 charts the serial UPDRS Part III scores
obtained at the end of weeks 1 and 4. By post hoc
analyses using an MMRM model, onset of action at
both CVT-301 dose levels was evident at 10 minutes
(the first assessment time) and the mean improvement in
motor scores remained significant versus placebo
through the 60-minute final assessment. At 60 minutes,
the week 4 treatment effect (50 mg vs placebo) exceeded
the week 1 treatment effect (35 mg vs placebo) by 4.3
points (95% CI, 0.3 to 8.3 points; P5 0.343).
At the end of week 1, 74% of the CVT-301 group
achieved a UPDRS Part III score reduction  6 points
by 30 minutes compared with 53% of the placebo
group. For a reduction  11 points, the proportion
was 55% versus 28%. At the end of week 4, 79% of
the CVT-301 group achieved a reduction  6 points
by 30 minutes compared with 33% of the placebo
group. For a reduction  11 points, the proportion
was 58% versus 28%.
Efficacy by Examiner Ratings
In the CVT-301 group, the proportion of patients
achieving an ON state in an examiner’s judgment
increased from 67% (28 of 42 patients) in week 1
(35-mg FPD) to 74% (29 of 39) and 78% (29 of 37)
in weeks 2 and 4, respectively (50-mg FPD). In the
placebo group, the proportion was 45% (18 of 40) in
week 1, 41% (16 of 39) in week 2, and 36% (13 of
36) in week 4.
Efficacy by PGI-C Self-Ratings
At the end of week 2 (ie, the end of the 35-mg self-
dosing period), 65% of the CVT-301 group and 44%
TABLE 1. Patients’ baseline characteristics (mITT population)
Variable
CVT-301 Group
(n 5 43)
Placebo Group
(n 5 43)
P Value
CVT-301 vs Placeboa
Age (years), mean (SD) 62.0 (8.4) 62.7 (9.1) 0.721
Sex, n (%) 0.110b
Male 25 (58) 32 (74)
Female 18 (42) 11 (26)
Race, n (%) 1.000c
White 41 (95) 42 (98)
Other 2 (5) 1 (2)
Time since PD diagnosis (years), mean (SD) 9.0 (3.8) 9.8 (4.0) 0.377
Time since emergence of motor fluctuations, years, mean (SD) 4.7 (3.9) 3.9 (3.3) 0.304
UPDRS, Part III score, mean (SD)
OFF 35.4 (12.0) 36.2 (12.1) 0.741
ON 16.2 (8.1) 18.9 (9.8) 0.170
OFF time, hours/day,d,e mean (SD) 5.7 (2.2) 5.8 (1.8) 0.860
OFF episodes, number/day,d,e mean (SD) 3.5 (1.1) 3.7 (1.0) 0.380
ON time, hours/day,d mean (SD)
With no dyskinesia 8.2 (3.4) 8.3 (3.5) 0.940
With nontroublesome dyskinesia 1.7 (2.5) 1.6 (2.6) 0.926
With troublesome dyskinesia 0.4 (1.1) 0.3 (1.0) 0.726
Modified Hoehn & Yahr stage when ON, n (%) 0.825
<2.5 27 (63) 26 (61)
2.5 16 (37) 17 (40)
Duration of LD treatment (years), mean (SD) 7.6 (3.8) 7.9 (4.0)f 0.717
LD dosage, mg/day, mean (SD) 687 (276) 853 (315) 0.011
LD doses, number/day, mean (SD) 5.6 (1.4) 6.1 (2.2) 0.261
Other PD drug use, n (%)
Dopaminergic agonists 31 (72) 26 (61) 0.254b
MAO-B inhibitors 23 (54) 14 (33) 0.050b
COMT inhibitors 17 (40) 17 (40) 1.000b
Amantadine 16 (37) 13 (30) 0.494b
aUnpaired t test, unless stated otherwise.
bChi-square test.
cFisher’s exact test.
dThree-day averages.
eIncluding early-morning OFF time.
fn 5 42.
COMT, catechol-O-methyltransferase; LD, levodopa; MAO-B, monoamine oxidase B; mITT, modified intent to treat; PD, Parkinson’s disease; SD, standard
deviation; UPDRS, Unified Parkinson’s Disease Rating Scale.
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of the placebo group rated their PD as improved,
28% and 51% rated it as unchanged, and 8% and
5% rated it as worse. At the end of week 4 (ie, the
end of the 50-mg self-dosing period), 72% of the
CVT-301 group and 46% of the placebo group rated
their PD as improved, 18% and 54% rated it as
unchanged, and 10% and 0% rated it as worse.
Efficacy by Diary Data
Across all diary-entry categories, the only statistically
significant difference between treatment groups was in
OFF time (Fig. 3), which at the end of week 4 showed
an LS mean decrease of 1.6 hours/day for CVT-301
dosed at 50 mg compared with 0.8 hours/day for pla-
cebo, a treatment effect of -0.9 hours/day (95% CI, -
1.7 to 0.0 hours/day; P 5 0.045). For CVT-301 dosed
at 35 mg, the LS mean OFF-time decrease at the end of
week 2 was 1.1 hours/day compared with 0.8 hours/
day for placebo, a treatment effect of -0.3 hours/day
(95% CI, -1.1 to 0.6 hours/day; P 5 0.498). At both
doses, changes in ON time with troublesome or non-
troublesome dyskinesia and in ON time with no dyski-
nesia were not significant (see Fig. 3).
FIG. 2. Mean serial UPDRS Part III score change for 2 CVT-301 dose
levels versus placebo (mITT population). *P < 0.05, **P < 0.01, ***P <
0.001 vs placebo, MMRM. mITT, modified intent to treat; MMRM,
mixed model for repeated measurements; SEM, standard error of the
mean; UPDRS, Unified Parkinson’s Disease Rating Scale.
FIG. 3. LS mean change in OFF time, in ON time with dyskinesia, and
in ON time with no dyskinesia throughout the study, based on 3-day
averages from PD diary entries (mITT population). *P < 0.05 vs pla-
cebo, MMRM. aTroublesome or nontroublesome. LS, least squares;
mITT, modified intent to treat; MMRM, mixed model for repeated
measurements; PD, Parkinson’s disease; SEM, standard error of the
mean.
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Safety
Twenty patients (47%) in the CVT-301 group and
14 patients (33%) in the placebo group reported
TEAEs (Table 2). By preferred term, the TEAEs with
an incidence  5.0% in the CVT-301 group were
dizziness, cough, and nausea, each of which was
reported in 3 patients (7%). As a TEAE, dyskinesia
was reported in 1 patient (2%) in each treatment
group. Two patients, both in the placebo group, expe-
rienced severe TEAEs: drop attack (also rated a seri-
ous TEAE) and dyskinesia.
One patient in the CVT-301 group and 2 in the pla-
cebo group experienced TEAEs that led to study-drug
dose adjustment. In the CVT-301 group, the events
were headache and nausea, at different times in the
same patient; in the placebo group, the events were
chest pain and dyskinesia, each in 1 patient. Two
patients in the CVT-301 group and 3 in the placebo
group experienced TEAEs leading to study-drug dis-
continuation. In the CVT-301 group, the events were
painful respiration and sputum discoloration. The
painful respiration occurred on treatment day 6 in a
67-year-old man whose medical history included con-
gestive heart failure, 2 myocardial infarctions, hyper-
tension, and anxiety. The event was rated as moderate
and as resolving the same day. The sputum discolora-
tion began on treatment day 20 in a 61-year-old man
who exhibited cough 5 days earlier, followed by influ-
enza symptoms. The event was rated as moderate and
as resolving 6 days after CVT-301 discontinuation, at
which time the patient’s cough was ongoing. In the
placebo group, the TEAEs leading to study-drug
discontinuation were bradykinesia, chest pain, and
wrist fracture. No deaths occurred during the study.
All other safety assessments identified no unexpected
concerns. Among spirometry findings, characteristic
PD-associated morphologies in flow-volume curves—
that is, sawtoothing and a rounded, delayed expira-
tory peak29,30—were noted at similar frequencies
across treatment groups. Mean values of all pulmo-
nary function parameters were within normal ranges,
showed no substantial difference between patients’
ON and OFF states, and showed no evidence of longi-
tudinal change in either treatment group.
Discussion
In a population of PD patients experiencing motor
fluctuations on orally administered LD, supplementary
self-administration of CVT-301, an LD inhalation
powder, provided rapid amelioration of OFF episodes.
Serial UPDRS Part III scores showed a treatment effect
at 10 minutes, the first assessment time. The treatment
effect was maximal at 30 minutes and was sustained
for 60 minutes. At 60 minutes, the effect was larger
at the higher dose (see Fig. 2), implying a longer effect
duration. Home-diary data showed a dose-ordered
reduction of the daily duration of OFF time with sta-
tistical significance versus the placebo at the higher
dose. At both dose levels, patients showed no signifi-
cant increase in ON time with dyskinesia. Although
patients were neither selected nor excluded based on
their ability to use the drug inhaler system, patients
were able to prepare and self-administer the treatment
with relative ease in their OFF states.
As measured by UPDRS Part III scores, the average
improvement in motor function was similar for both
dose levels. However, the average difference from
TABLE 2. Treatment-emergent adverse events (safety population)
TEAE
Incidence,n (%)
CVT-301 Group
Placebo Group
(n 5 43)
At any time
(n 5 43)
While Using 35 mg
(n 5 42)
While Using 50 mg
(n 5 42)
Summary
Any TEAE 20 (47) 17 (41) 9 (21) 14 (33)
Any study-drug–related TEAE 10 (23) 8 (19) 6 (14) 9 (21)
Any severe TEAE 0 0 0 2 (5)
Any serious TEAE 0 0 0 1 (2)
Any TEAE leading to study-drug dose adjustment 1 (2) 1 (2) 1 (2) 2 (5)
Any TEAE leading to study-drug discontinuation 2 (5) 1 (2) 1 (2) 3 (7)
Any TEAE leading to death 0 0 0 0
By Preferred Terma
Dizziness 3 (7) 3 (7) 0 2 (5)
Cough 3 (7) 2 (5) 1 (2) 1 (2)
Nausea 3 (7) 1 (2) 2 (5) 0
Headache 2 (5) 2 (5) 0 2 (5)
Edema peripheral 2 (5) 0 2 (5) 1 (2)
Anxiety 2 (5) 0 2 (5) 0
Sputum discolored 2 (5) 0 2 (5) 0
aPer Medical Dictionary for Regulatory Activities version 15.1. The list includes all TEAEs reported in more than 1 patient in either treatment group.
TEAE, treatment-emergent adverse event.
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placebo was numerically greater after the 50-mg dose,
at least partly because of a decrease in placebo
response in weeks 2 and 4 compared with week 1. In
PD clinical research, a strong placebo response is typi-
cal and may reflect activation of residual nigrostriatal
dopaminergic function by expectation of treatment
benefit.31,32 Thus, the observed decrease might repre-
sent treatment unmasking as the trial proceeded by
cumulative experience with an inert intervention. The
average improvement associated with active treat-
ment—9.9 points after week 1, 10.2 points after week
2, and 10.0 points after week 4—greatly exceeded the
reported minimum values for a clinically relevant
change in Part III scores.27,33-36 In analyses based on
cross-sectional Part III data representing all PD
stages,27 2.5 points has been judged to be a minimal
CID, 5.2 to be a moderate CID, and 10.8 to be a large
CID. In the present study, a majority of patients in the
CVT-301 group achieved an 11-point change (55% in
week 1 and 58% in week 4).
Throughout the 4 weeks of its use, CVT-301 was
generally well tolerated at both dose levels. Among
the TEAEs most frequently reported in the CVT-301
group, nausea, a symptom commonly associated with
dopaminergic therapies in PD patients, caused only 1
patient to reduce the CVT-301 dose and no patient to
withdraw from the study. Dizziness caused no CVT-
301 dose reductions or discontinuations, and its inci-
dence in the placebo group (5%) resembled that in the
CVT-301 group (7%). Although dyskinesia is associ-
ated with long-term LD use,3 TEAE incidence corro-
borated the study’s diary data in showing no increase
in dyskinesia occurrence. Dyskinesia is also associated
with peaks in LD plasma level.37 However, patients’
self-treatment of their OFF episodes would presum-
ably have occurred during troughs in the level.
Because CVT-301 is an inhaled drug, cough was of
special interest. In both treatment groups, all reported
instances of cough were mild, none led to dose reduc-
tion or discontinuation, and no patient in either group
reported dyspnea, wheezing, or bronchospasm.
The study may have been limited by requiring
patients to restrict their study-drug self-administration
to not more than 3 times daily despite having, on
average, a reported baseline OFF-episode frequency of
3.6 per day (albeit including early-morning off time).
Indeed, the baseline OFF-episode frequency ranged up
to 7 per day, yet study-drug usage averaged only 2.1
times per day. Conceivably, patients may have held
back on study-drug use each day to keep it available
for potential severe episodes or times of need to be
ON. Patients may also have refrained from using the
study drug soon before their usual PD treatment.
Although PGI-C self-ratings of PD improvement
favored CVT-301, these ratings were global impres-
sions following weeks of study-drug use, rather than
patients’ impressions of benefit during specific OFF
episodes. As a further limitation, the study assessed
35- and 50-mg dosing only as sequential treatments.
Hence, the differences observed between them might
reflect overall treatment duration rather than dose
strength. The study did not assess the potential utility
of CVT-301 for treating morning akinesia, which is
common in patients with wearing-off responses to
oral LD.
Among available PD pharmacotherapies, the dopa-
minergic agonist apomorphine offers the rapid action
required to lessen OFF episodes.38 In patients receiv-
ing repeated subcutaneous injections until their
response resembled their usual levodopa response, a
UPDRS Part III effect size of 23.8 points was
achieved, and 1-month outpatient usage was reported
to abort 95% of OFF episodes versus 23% for
placebo.39 Studies of randomized withdrawal40,41 and
long-term open-label self-treatment42,43 were also
positive. However, apomorphine is ineffective if taken
orally, and subcutaneous injection often requires
premedication with an antiemetic. Currently-marketed
formulations also present safety and tolerability issues
including nausea, vomiting, and development of
subcutaneous nodules at injection sites.44 Other
forms of apomorphine have been or are in develop-
ment.45-48
Conclusions
OFF-episode reversal by a well-tolerated noninvasive
intervention remains an important unmet clinical
need. In the present study, inhalation of LD formu-
lated as CVT-301 achieved rapid improvement of OFF
states and reduced daily OFF time without an increase
in dyskinesia or in severe or serious TEAEs. The
study’s findings support continued investigation of
CVT-301 for rapid treatment of OFF episodes.
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